Missense and nonsense mutations in the glucokinase gene have recently been shown to result in maturity-onset diabetes of the young (MODY), a subtype of non-insulin-dependent diabetes mellitus with early age of onset. Glucokinase catalyzes the formation of glucose-6-phosphate and is involved in the regulation of insulin secretion and integration of hepatic intermediary metabolism. Nucleotide sequence analysis of exon 4 and its flanking intronic regions of the glucokinase gene, in four hyperglycemic individuals of a MODY family, revealed a deletion of 15 base pairs, which removed the t of the gt in the donor splice site of intron 4, and the following 14 base pairs. This deletion resulted in two aberrant transcripts, which were analyzed by reverse transcription of RNA from lymphoblastoid cells obtained from a diabetic patient. In one ofthe abnormal transcripts, exon 5 is missing, while in the other, the activation of a cryptic splice site leads to the removal of the last eight codons of exon 4. This intronic deletion in a donor splice site seems to cause a more severe form of glucose intolerance, compared with point mutations described in glucokinase. This might be due to a more pronounced effect on insulin secretion. (J. Clin. Invest. 1993. 
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM)' is a heterogeneous disorder of glucose homeostasis characterized by defects in insulin secretion and insulin action ( 1) . The familial aggregation of NIDDM and the high concordance in identical twins indicate the important contribution of heredity to the development of the disease (2) . Although most forms of NIDDM do not exhibit simple mendelian inheritance, a sub- 1 . Abbreviations used in thispaper: GCK, glucokinase; IVGTT, intravenous glucose tolerance test; MODY, maturity-onset diabetes of the young; NIDDM, non-insulin-dependent diabetes mellitus; OGTT, oral glucose tolerance test; PM, point mutation; RT, reverse transcription; SSCP, single-strand conformation polymorphism. type of NIDDM with an early age of onset, maturity-onset diabetes of the young (MODY) is characterized by a clear autosomal dominant transmission (3) .
Close linkage between MODY and the glucokinase locus on chromosome 7p has recently been demonstrated in a French cohort and in one English MODY family (4, 5) . 16 different nonsense and missense mutations in the glucokinase gene have been identified in affected members ofthese MODY families (6) (7) (8) (9) . These mutations were shown to impair the enzymatic activity of the encoded protein (10) . The glycolytic enzyme glucokinase (GCK, ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1.) is specifically synthesized in the liver and in pancreatic beta cells. It plays a key role in the regulation of glucose homeostasis: in the hepatocytes, the phosphorylation ofglucose by glucokinase facilitates the uptake and metabolism of glucose by maintaining a gradient for glucose transport into these cells, thereby regulating hepatic glucose disposal. In beta cells, glucokinase appears to comprise part ofthe glucose-sensing mechanism and to be involved in the regulation of insulin secretion ( 1 1-13).
Here we report an intronic deletion in the GCK gene in a MODY family, which affects a donor splice site. Since GCK expression is tissue specific, we had to investigate the effects of this intronic deletion on the structure of GCK mRNA by amplification of the GCK illegitimate transcripts present in lymphoblastoid cells.
Methods
Subjects. Family information and clinical data were obtained from seven members of the family F423 (Table I ). This family belongs to a panel of MODY kindreds collected in France through a multimedia campaign (14) . MODY was ascertained in the kindred by the presence of NIDDM in three consecutive generations and three patients diagnosed before 25 Patients received no other medication. done by PCR amplification of each of the 12 exons of the glucokinase Glucose tolerance status and insulin secretory profile of patients gene (7), followed by SSCP analysis as described (19) . from family F423 were compared with those of six MODY patients Automatic direct sequencing. PCR amplified genomic DNA fragcarrying a point mutation (PM) in glucokinase gene (Tables I and II). ments (the normal and the deleted alleles) were isolated using a kit PM patients belong to two kindreds presenting with different muta-(Qiagen, Coger, France), before direct double-stranded DNA sequenctions (Glu-300-Gln and Gly-I75-Arg; reference 9). Seven lean, healthy ing. The different cDNA-PCR products (the normal and the aberrant individuals with no diabetic relatives were also used as a control group transcripts) were isolated from low-melting agarose by aspirating di- (Tables I and II) . Patients and individuals in the control group gave rectly the band visualized by ethidium bromide staining. DNA temfully informed consent before taking part in the study.
plates were sequenced directly using a DNA sequencer (373A; Applied Insulin secretion was evaluated by measuring plasma insulin reBiosystems, Foster City, CA), and a dideoxy-cycle-sequencing protosponse to an intravenous glucose tolerance test (IVGTT). A bolus of col in the presence ofthe specific primers together with fluorescence-la-30% dextrose (0.5 g/kg body wt) was injected over 3 min. Time 0 was beled dideoxy terminators according to Sanger (20) .
the end of the injection. Blood was sampled for glucose and insulin cDNA synthesis to detect illegitimate transcription. EBV-transmeasurements at -5, 1, 3, 5, 10, and 15 min. First-phase insulin secreformed lymphocytes from both affected and unaffected individuals tion was expressed as the sum of the values of 1 + 3 min as this has were cultured and total RNA was prepared according to the method of become a standard representation of IVGTT results (16) .
Chirgwin et al. (21) . cDNA synthesis was carried out as described (22) . Plasma insulin was measured by radio immunoassay. Plasma glu-
The yield of PCR product from reverse transcribed GCK cDNA was cose was measured by the glucose-oxidase method (glucose analyzer II;
increased specifically by two rounds of PCR amplification using a pair Beckman Instruments, Inc., Fullerton, California). Data are expressed of external primers, DI and D2, for the first round and a couple of as mean±SD. Statistics are Mann-Whitney's U test for nonparametric internal (nested) primers, D3 and D4 to enhance the specificity and the data. IVGTT and hyperglycemic clamp data from PM patients and product yield (Fig. 1) . The complementary sequences for the PCR from individuals N2234 and N2235 were previously reported elseprimers D2 and D4 were in exon 6 and those for Dl and D3 were in where (17). exon 2 (Fig. 1) . The PCR amplification is as follows: 10 l ofthe 40-IA SSCP (single-strand conformation polymorphism) analysis. Genoreaction mix containing the reverse transcribed GCK cDNA strands mic DNA was isolated from peripheral blood leukocytes using stanwere added to a 50-Al volume containing 20 pmol of PCR primers Dl ing to the direction of the extension reaction. rc 3' The normal size of the RT-PCR products is shown. ( Hybridization ofproduct ofRT-PCR II with internal oligo-probes.
The product of RT-PCR-II was hybridized with internal oligo-probes, D5 (5'-TGACCGGCACTGCTGAGATG-3'), located at the 3' end of exon 3 in the GCK gene, and D6 ( 5'-AGGGAACAATGTCGTGGG-GC-3'), located in exon 5. 3 Al of the amplified product were electrophoresed on a denaturant (6% acrylamide, 8 M (Fig. 2 B) .
Identification ofan intronic deletion. Direct sequencing of this genomic region in the affected heterozygote N2235 showed two different sequences: one is the expected normal sequence, the other showed a deletion of 15 bp, which removed the t of the gt dinucleotides in the splice donor site ofintron 4, and the following 14 bp (Fig. 3 B) . The acceptor site and the branch site remained unchanged. This heterozygous defect was confirmed after sequencing of the separated alleles (Fig. 3 C) . The deletion was present in all affected individuals from family F423 but not in the nonaffected individuals.
Exploration ofmRNA in a patient with the intronic deletion To investigate the effect of this genomic deletion on the structure and the sequence of the encoding mRNA, lymphoblasts were cultured from one affected individual (N2235) of family F423 and from one unrelated individual. Total RNA was extracted, and cDNA species were synthesized by reverse transcription. The illegitimate specific cDNA region from exon 2 to exon 6 was amplified by PCR, and found to have one band of normal size (448 bp) in the control sample, and four different bands in the patient sample: an upper faint band, a band of424 bp, a shadow band beneath 424 bp, and a 352-bp band (Fig. 4  A) . The lowest band (352 bp) was likely to be a truncated mRNA lacking the 96 bp exon 5, but the other three bands remained of unknown origin. Southern blot analysis of cDNA products with a labeled internal oligo-probe, D5, located at the 3' end of exon 3, confirmed the specificity of the RT in the presence of mixtures of related products that differ in length (23) . The lack of hybridization with probes D5 (Fig. 4 4, A and B; Fig. 5]) ; and an alternatively spliced mRNA product, resulting from the activation of a cryptic splice site gt, located in exon 4,24 bp upstream ofthe consensus site gt (424 bp, splice variant II [ Fig. 5] ). This abnormal mRNA lacks the last eight codons of exon 4 and remains in-frame. To verify whether SSCP has not failed to detect a mutation that alters the splice sites around exon 5, we have sequenced the 3' end of intron 4 (from 52 bp upstream of exon 5) and intron 5. It was found to be normal in all the diabetic and normoglycemic members of kindred F423 (results not shown).
Five consecutive preparations of products of RT-PCR II were made from the reversed transcribed cDNA, in both patient N2235 and the unrelated control individual. Direct sequencing ofthe cDNA fragments in the patient showed, in only one experiment out of five, an insertion of the first 10 bp from intron 2 between exon 2/exon 3, which was associated with the skipping of exon 5 in the same mRNA molecule (data not shown). This insertion occurred by activation of a gt cryptic splice site 11 bp downstream from the gt consensus donor site. Iftranslated, this aberrant transcript would lead to a frameshift introducing a stop codon (TGA) at the beginning of exon 3. This insertion was never observed in the control cDNA despite repeated experiments.
Clinical and metabolic.profile
All the individuals in the kindred F423 carrying the deletion described above present with abnormal glucose tolerance (Table II). Fasting and 2-h plasma glucose were not different in affected individuals from F423 and PM individuals. However, two findings suggest that glucose tolerance was more severely affected in the kindred F423 than in PM patients. First, the area under the glucose curve during the OGTT was significantly larger in F423 individuals than in PM individuals (Table II). Second, although the glycated hemoglobin was not significantly different in both groups, three out of four patients in F423 against one out of six of the PM patients were treated by hypoglycemic agents. First-phase insulin secretion was not significantly different in the two groups. However, one can note that in the elder individuals of F423 (N2234 and N2687), the first-phase insulin secretion was lower than 1 SD below the mean in PM individuals.
Discussion
Several nonsense and missense mutations have recently been identified in the GCK gene as a cause of hyperglycemia in MODY (6, 7, 9) and in a few late-onset NIDDM families (8, 24) . We here report a deletion in the 5' splice site of intron 4 in the GCK gene that is responsible for diabetes in a French MODY family.
Expression studies of mutant alleles of GCK after site-directed mutagenesis would not be possible in the case of an intronic mutation affecting a splice site, until the abnormal mRNAs have been identified. Thus, in individuals of family F423 carrying a deletion in intron 4, it was of interest to analyze the encoded GCK mRNA to understand the molecular basis of the phenotypic effect of this DNA alteration. The glucokinase gene is expressed only in liver and in pancreatic beta cell (12 ) , tissues that are not easily available for investigation in human. Amplification by PCR of illegitimate transcripts has proven to be a sensitive method to scan for mutations in any gene expressed in any cell type (25) , even when mutations occurred in highly tissue-specific genes, such as the dystrophin gene (25) , the anti-Mullerian hormone gene (26) and the type IV collagen alpha 5 chain gene (22) . We have taken advantage of illegitimate transcription to amplify the GCK cDNA from lymphoblastoid cells and to demonstrate that this deletion was seemingly responsible for diabetes in this kindred. Although these abnormalities in GCK mRNA were found in cultured lymphoblastoid cells, it is likely that in pancreas and liver, splicing is similarly impaired. Chelly et al. demonstrated that in regions of the dystrophin gene surrounding different deletions, processing of truncated transcripts were identical in specific (muscle tissue) and in nonspecific cells (lymphoid cells) (27) . PCR amplification of lymphoblast mRNA showed two major species of aberrant truncated mRNA: one with the skipping of exon 5 and the other with an activation of a cryptic splice site upstream from the deleted splice site, resulting in the splicing of eight codons at the end of exon 4, but maintaining the reading frame. In patient N2235, only the aberrant reverse transcripts have been found. We did not succeed in isolating the normal reverse transcript despite repeated efforts. This might be due to limitations of the PCR technique, which, in the case of two differently sized alleles, fail sometimes to amplify the longer allele (B. Knebelmann, unpublished data).
Aberrant splicing, caused by alteration of 5'-splice sites, have been shown previously: Sakuraba et al. reported that of22 characterized 5'-splice site mutations in various mammalian genes, 77% resulted in exon skipping, whereas 27% activated cryptic splice sites (28) . In the MODY family F423, the abnormal 424 bp transcript results from the activation of a cryptic splice site situated in exon 4, close to and upstream (24 bp) the deleted consensus gt site, as usually reported (28, 29) . The sequence surrounding this cryptic site (CT gtgagg) is in agreement with the consensus sequence of5 '-splice site in mammals: AG gta (or g) agt for the positions -2 to +6 based on the beginning of the intron where the splice site is situated. The positions of -2, -1, and from +4 to +6 are less important and may have different nucleotides (28, 30) .
In most cases reported previously (28, 29, 31) , when the 5 '-splice site was altered, the skipped exon was exclusively the exon located on 5' of the altered donor splice site. The mechanisms involved in family F423, leading to the skipping of the exon situated on 3' of the affected donor splice site, remain obscure. A possible explanation is that the genomic deletion of the 5'-splice site in intron 4 would affect the normal function of the transcriptional machinery, as it has been described by Leroux et al. (32) . The remaining sequence at the 5'-part ofintron 4 left after the deletion, gggcag (+ 1 to +6), could be recognized as a donor splice site and used with the intron 5 3'-acceptor splice site (ag), instead of the intron 4 (30) . The third type of aberrant GCK messenger observed (with an insertion of the first 10 bp from intron 2 between exon 2/exon 3 and the skipping ofexon 5) seems to be rare, since we found it in only one RT-PCR experiment out of five. The mechanism that leads to this transcript is unknown.
The genomic deletion in intron 4 ofthe GCK gene is likely to be responsible for the hyperglycemia in kindred F423 for several reasons: (a) the defect in GCK cosegregated with diabetes in this family, and the likelihood of the odds score (lodscore) for linkage is highly significant (+4.85, i.e., odds for linkage of almost I0':1, data not shown) using an autosomal dominant model (6); (b) this deletion was not present in unrelated normal and late-onset NIDDM individuals; and (c) this deletion resulted in the synthesis of aberrant truncated GCK mRNA species, which probably encode a GCK enzyme with decreased or null activity. A molecular model of the glucokinase protein using the related yeast hexokinase B crystal structure has shown that the region encoded by exon 5, which is missing in splice variant I (Fig. 5) , plays an important role in binding glucose to GCK ( 10) . Indeed, most ofthe point mutations reported in MODY families are clustered in exons 5, 7, and 8 ( 10) . The last eight codons of exon 4, which are lacking in splice variant II, encode a beta strand region of the enzyme. Their absence might alter the conformational structure of the enzyme, leading to a decrease of its activity (10) . Thus, the putative decrease in GCK activity could account for the hyperglycemic phenotype of affected members of family F423, as GCK is a rate-limiting enzyme for glycolysis in pancreatic beta cell and in liver and is involved in the regulation of insulin secretion and in hepatic glucose uptake ( 12, 13) . Since GCK seems to act as a monomer, the insulin secretory defect in heterozygous individuals could be the result of a gene dosage effect. Meglasson and Matschinsky ( 11 ) have suggested that a modest decrease in glucokinase activity may shift the threshold for insulin secretion in response to a physiological glucose challenge from 5 to 6 mM. In this regard, we have previously demonstrated that mutant GCK in four MODY families (including F423) leads to chronic hyperglycemia by raising the threshold level of circulating glucose, which induces insulin secretion, and by the inability ofthe pancreatic beta cell to sustain insulin secretion through a prolonged hyperglycemic stimulus ( 17).
It is difficult to determine the proportion of each transcript of the mutant GCK in patients of family F423, for the method of RT-PCR does not allow quantification of illegitimate transcripts (25) . The percentage of splice variants I and II might not be equal from one patient to another in this kindred. It might be speculated that splice variant I (with exon 5 skipped) leads to a more important decrease in the activity of the enzyme than splice variant II (lacking the last eight codons in exon 4). Thus, the proportion of each abnormal transcript might also account for the differences in the severity of the secretory defects observed in different individuals of F423, although other genetic or environmental factors might contribute to this defect.
Different phenotypic expression of mutants of GCK has been reported in MODY families, and it has been suggested that clinical and metabolic characteristics of diabetic patients may reflect the nature and/or the position of the mutation (10) . Moreover, expression studies of mutant alleles of GCK have shown that mutations having a mild effect on GCK activity lead to less severe forms ofdiabetes than mutations resulting in a dramatic decrease of the Vmax of the enzyme (10) . The deletion in family F423 probably results in an important decrease of the enzyme activity. This may account for the relatively more severe phenotype of affected members in this family, in comparison with the PM individuals.
We have recently found another intronic deletion in GCK in a 9-yr-old hyperglycemic child, with a strong family history ofdiabetes. Nucleotide sequencing analysis revealed a deletion of 33 bp in the beginning of intron 5, which removed the consensus donor splice site gt (with cc instead after the deletion) of intron 5 (data not shown). The association of diabetes with this deletion confirms the deleterious effect on glucose homeostasis of DNA deletions that remove donor splice sites ofGCK.
In conclusion, this study demonstrated that a deletion of a donor splice site in intron 4 
